Clinical trial
-
Older patients are underrepresented in the clinical trials that determine the standards of care for oncological treatment. We conducted a review to identify whether there have been age-restrictive inclusion criteria in clinical trials over the last twenty five years, focusing on patients with metastatic gastroesophageal cancer.
9p vielonmusk 21-01-2022 12 1 Download
-
Safety and efficacy of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction (GEJ) cancer could be demonstrated in predominantly Asian cohorts, whereas data in Western patients outside of clinical trials are vastly missing.
10p vielonmusk 21-01-2022 16 0 Download
-
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer mortality in the world. Therefore, more and more studies are developing novel therapies to treat this disease. The pre-clinical trials on animals are a vital step to evaluate the efficacy as well as side effects of these novel therapies. Hence, this study aimed to develop the murine model of HCC using 3 kinds of mice: NOD/SCID, nude and Balb/c mice.
7p larachdumlanat127 02-01-2021 13 2 Download
-
Evaluating shaping result of ProTaper Next and ProTaper Universal system when performed on upper premolars’ root canal of the elderly. Evaluating shaping result of ProTaper Next and ProTaper Universal system when performed on upper premolars’ root canal of the elderly.
29p cothumenhmong6 17-07-2020 10 2 Download
-
AR-42, a new orally bioavailable, potent, hydroxamate-tethered phenylbutyrate class I/IIB histone deacetylase inhibitor currently is under evaluation in phase 1 and 2 clinical trials and has demonstrated activity in both hematologic and solid tumor malignancies. This report focuses on the preclinical characterization of the pharmacokinetics of AR-42 in mice and rats.
9p caothientrangnguyen 09-05-2020 18 3 Download
-
Staphylokinase (SAK) is a 15.5-kDa protein fromStaphy-lococcus aureusthat activates plasminogenby forminga1 : 1 complex with plasmin. Recombinant SAK has been shown in clinical trials to induce ®brin-speci®c clot lysis in patients withacutemyocardial infarction.However, SAKelicits high titers of neutralizing antibodies. Biochemical and protein engineering studies have demonstrated the feasibility of generatingSAKvariantswith reducedantigenicity yet intact thrombolytic potency.
7p research12 23-04-2013 40 3 Download
-
Onconase, a member of the ribonuclease superfamily, is a potent cytotoxicagent that isundergoingphase II/IIIhuman clinical trials as an antitumor drug. Native onconase from Rana pipiensand its amphibian homologs have an N-ter-minal pyroglutamyl residue that is essential for obtaining fully active enzymes with their full potential as cytotoxins. When expressed cytosolically in bacteria, Onconase is isolated with an additional methionyl (Met1) residue and glutaminyl insteadof a pyroglutamyl residue at position 1 of the N-terminus and is consequently inactivated....
9p dell39 03-04-2013 30 3 Download
-
Several ribonucleases, including onconase anda-sarcin, are known to be toxic to tumor cells. On the other hand, although its structure is relatedto thatofa-sarcin,RNase T1 is noncytotoxic because of its inability to internalize into tumor cells. In this study, we internalized RNase T1 into human tumor cells via a novel gene transfer reagent, hem-agglutinating virus of Japan (HVJ) envelope vector, which resulted in cell death.
6p dell39 03-04-2013 35 4 Download
-
Because clinical trials of pharmacological neuroprotective strategies in stroke have been disappointing, attention has turned to the brain’s own endogenous strategies for neuroprotection. Two endogenous mechanisms have been characterized so far, namely ischemic preconditioning and ische-mic postconditioning.
12p vinaphone15 27-02-2013 32 2 Download
-
Stroke is the third leading cause of death in industrialized countries but efficacious stroke treatment is still an unmet need. Preclinical research indi-cates that different molecules afford protection from ischemic neurodegen-eration, but all clinical trials conducted so far have inexorably failed.
10p vinaphone15 27-02-2013 36 1 Download
-
Onconase (ONC) is a member of the ribonuclease A superfamily that is toxic to cancer cells in vitro andin vivo. ONC is now in Phase IIIb clinical trials for the treatment of malignant mesothelioma. Internalization of ONC to the cytosol of cancer cells is essential for its cytotoxic activity, despite the apparent absence of a cell-surface receptor protein.
12p vinaphone15 25-02-2013 27 3 Download
-
Small molecules that activate the transcriptional function of wild type p53 have proved active as anti-cancer drugs in preclinical models and are now entering clinical trial. The complexity of the upstream p53 signaling pathway offers many targets for the devel-opment of such activators and the action of Mdm2 inhibitors, kinase inhibitors, sirtuin inhibitors and low doses of actinomycin D will be described among other examples.
3p viettel02 22-02-2013 40 3 Download
-
Neither randomized clinical trials nor meta- analysis are available and evidence is based on a number of retrospective studies with multivariate for mortality risk factors or data from national cancer registries (Gilliland et al., 1997; Hundahl et al., 1998). Unfortunately, very remarkable differences in patient’s selection, staging systems, and clinical management affect the available studies. In particular, radioiodine treatment is not routinely carried out in a standard manner and outcome results of different studies are thus not comparable (Sciuto et al., 2009).
180p wqwqwqwqwq 20-07-2012 83 6 Download
-
Cause-specific survival is commonly estimated in cancer clinical trials and only those deaths which can be attributed to the cancer in question are considered to be events, while all other deaths are considered censorings. Using cause-specific survival to estimate net survival requires that reliably coded information on cause of death is available. The distinguishing feature of survival analysis is that at the end of the follow-up period the event (such as death due to cancer) will probably not have occurred for all patients.
226p wqwqwqwqwq 20-07-2012 83 5 Download
-
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Biomarkers in T cell therapy clinical trials
9p dauphong6 05-01-2012 41 6 Download
-
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Defining a minimal clinically important difference for endometriosis-associated pelvic pain measured on a visual analog scale: analyses of two placebo-controlled, randomized trials
7p panasonic05 23-12-2011 58 2 Download
-
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: The WRITTEN-HEART study (expressive writing for heart healing): rationale and design of a randomized controlled clinical trial of expressive writing in coronary patients referred to residential cardiac rehabilitation
8p panasonic05 22-12-2011 48 4 Download
-
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Circulating Immune Complexes and trace elements (Copper, Iron and Selenium) as markers in oral precancer and cancer : a randomised, controlled clinical trial
10p panasonic05 22-12-2011 44 5 Download
-
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Future oriented group training for suicidal patients: a randomized clinical trial
7p thulanh29 18-12-2011 41 3 Download
-
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials
12p thulanh29 18-12-2011 90 7 Download